Advancements in dry powder delivery to the lung

Drug Development and Industrial Pharmacy

Volumn 34, Issue 9, 2008, Pages 948-959

  Son, Yoen Ju ^a   McConville, Jason T ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Carrier particles; Mechanical inhalation devices; Passive inhalation devices; Powder dispersion

Indexed keywords

BUDESONIDE; CROMOGLYCATE DISODIUM; FORMOTEROL; GROWTH HORMONE; INSULIN; LACTOSE; RECOMBINANT HUMAN INSULIN; SALBUTAMOL;

AEROSOL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; LUNG; METERED DOSE INHALER; POWDER INHALER; REVIEW;

CHEMISTRY, PHARMACEUTICAL; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE; POWDERS;

EID: 52149086776     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802235902     Document Type: Review

References (107)

1. Acerbi, D., Brambilla, G., & Kottakis, I. (2007). Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite (R) technology. Pulm. Pharmacol. Ther., 20, 290-303.
2. American Diabetes Association. (2003). Insulin administration. Diabetes Care, 26, S121-S124.
3. Ashurst, I., Malton, A., Prime, D., & Sumby, B. (2000). Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. Today, 3, 246-256.
4. Ben-Jebria, A., Eskew, M. L., & Edwards, D. A. (2000). Inhalation system for pulmonary aerosol drug delivery in rodents using large porous particles. Aerosol Sci. Technol., 32, 421-433.
5. Bindra, S., & Cedalu, W. T. (2002). Inhaled therapeutic systems. Curr. Opin. Investig. Drugs, 3, 758-762.
6. Borgstrom, L., Asking, L., & Lipniunas, P. (2005). An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J. Aerosol Med., 18, 304-310.
7. Borgstrom, L., Bondesson, E., Moren, F., Trofast, E., & Newman, S. P. (1994). Lung deposition of budesonide inhaled via Tubuhaler® - A comparison with terbutaline sulphate in normal subjects. Eur. Respir. J., 7, 69-73.
8. Brambilla, G., Ganderton, D., Garzia, R., Lewis, D., Meakin, B., & Ventura, P. (1999). Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int. J. Pharm., 186, 53-61.
9. Braun, M. A., Oschmann, R., & Schmidt, P. C. (1996). Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the twin impinger. Int. J. Pharm., 135, 53-62.
10. Breeders, M. E. A. C., Molema, J., Vermue, N. A., & Folgering, H. Th. M. (2001). Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur. Respir. J., 18, 780-783.
11. Brwon, B. A. S., Rasmussen, J. A., Becker, D. P., & Friend, D. R. (2004). A piezo-electronic inhaler for local & systemic applications. Drug Deliv. Technol., 4, 90-93.
12. Cappelleri, J. C., Cefalu, W. T., Rosenstock, J., Kourides, I. A., & Gerber, R. A. (2002). Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin. Ther., 24, 552-564.
13. Cegla, U. H. (2004). Pressure and inspiratory flow characteristics of dry powder inhalers. Respir. Med., 98, S22-S28.
14. Chrystyn, H. (2006). Closer to an "ideal inhaler" with the easyhaler (R) - an innovative dry powder inhaler. Clin. Drug Investig., 26, 175-183.
15. Cochrane, M. G., Bala, M. V., Downs, K. E., Mauskopf, J., & Ben-Joseph, R. H. (2000). Inhaled corticosteroids for asthma therapy - patient compliance, devices, and inhalation technique. Chest, 117, 542-550.
16. Cook, R. O., Pannu, R. K., & Kellaway, I. W. (2005). Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release, 104, 79-90.
17. Corrigan, D. O., Healy, A. M., & Corrigan, O. I. (2006). Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur. J. Pharm. Biopharm., 62, 295-305.
18. Cramer, J., Okikawa, J., & Clauson, P. (2003). Compliance with inhaled insulin treatment using AERx® iDMS insulin diabetes management system. Diabetes, 52, A103-A103.
19. Crowder, T. M. (2004). Vibration technology for active dry-powder inhalers. Pharm. Technol., 28, 52-59.
20. Dalby, R., Spallek, M., & Voshaar, T. (2004). A review of the development of Respimat® soft Mist™ Inhaler. Int. J. Pharm., 283, 1-9.
21. De Boer, A. H., Gjaltema, D., Hagedoorn, P., & Frijlink, H. W. (2004). Comparative in vitro performance evaluation of the Novopulmon® 200 Novolizer® and Budesonid-ratiopharm® Jethaler: Two novel budesonide dry powder inhalers. Pharmazie, 59, 692-699.
22. De Boer, A. H., Hagedoorn, P., Gjaltema, D., Goede, J., & Frijlink, H. W. (2003). Air classifier technology (ACT) in dry powder inhalation - Part I. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm., 260, 187-200.
23. De Boer, A. H., Hagedoorn, P., Gjaltema, D., Goede, J., & Frijlink, H. W. (2006a). Air classifier technology (ACT) in dry powder inhalation - Part 3. Design and development of an air classifier family for the Novolizer® multidose dry powder inhaler. Int. J. Pharm., 310, 72-80.
24. De Boer, A. H., Hagedoorn, P., Gjaltema, D., Goede, J., & Frijlink, H. W. (2006b). Air classifier technology (ACT) in dry powder inhalation - Part 4. Performance of air classifier technology in the Novolizer® multi-dose dry powder inhaler. Int. J. Pharm., 310, 81-89.
25. De Boer, A. H., Winter, H. M. I., & Lerk, C. F. (1996). Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers.1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int. J. Pharm., 130, 231-244.
26. Dellamary, L. A., Tarara, T. E., Smith, D. J., Woelk, C. H., Adractas, A., Costello, M. L., Gill, H., & Weers, J. G. (2000). Hollow porous particles in metered dose inhalers. Pharm. Res., 17, 168-174.
27. DeLong, M., Wright, J., Dawson, M., Meyer, T., Sommerer, K., & Dunbar, C. (2005). Dose delivery characteristics of the AIR® pulmonary delivery system over a range of inspiratory flow rates. J. Aerosol Med., 18, 452-459.
28. Dolovich, M. (1999a). New delivery systems and propellants. Can. Respir. J., 6, 290-295.
29. Dolovich, M. (1999b). New propellant-free technologies under investigation. J. Aerosol Med., 12, S9-S17.
30. Duddu, S. P., Sisk, S. A., Walter, Y. H., Tarara, T. E., Trimble, K. R., Clark, A. R., Eldon, M. A., Elton, R. C., Pickford, M., Hirst, P. H., Newman, S. P., & Weers, J. G. (2002). Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm. Res., 19, 689-695.
31. Dunbar, C. A., Hickey, A. J., & Holzner, P. (1998). Dispersion and characterization of pharmaceutical dry powder aerosols. KONA, 16, 7-44.
32. Dunbar, C., Scheuch, G., Sommerer, K., DeLong, M., Verma, A., & Batycky, R. (2002). In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int. J. Pharm., 245, 179-189.
33. Edwards, D. A., Hanes, J., Caponetti, G., Hrkach, J., BenJebria, A., Eskew, M. L., Mintzes, J., Deaver, D., Lotan, N., & Langer, R. (1997). Large porous particles for pulmonary drug delivery. Science, 276, 1868-1871.
34. Ellis, S. L., Gemperline, K. A., & Garg, S. K. (2007). Review of phase 2 studies utilizing the AIR® particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol. Ther., 9, S48-S56.
35. Fenton, C., Keating, G. M., & Plosker, G. L. (2003). Novolizer® - a multidose dry powder inhaler. Drugs, 63, 2437-2445.
36. Guidance for Industry, Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. (1998).
37. Harper, N. J., Gray, S., De Groot, J., Parker, J. M., Sadrzadeh, N., Schuler, C., Schumacher, J. D., Seshadri, S., Smith, A. E., Steeno, G. S., Stevenson, C. L., Taniere, R., Wang, M., & Bennett, D. B. (2007). The design and performance of the Exubera® pulmonary insulin delivery system. Diabetes Technol. Ther., 9, S16-S27.
38. Hendeles, L., Colice, G. L., & Meyer, R. J. (2007). Current concepts - withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N. Engl. J. Med., 356, 1344-1351.
39. Hirst, P. H., Newman, S. P., Clark, D. A., & Hertog, M. G. L. (2002). Lung deposition of budesonide from the novel dry powder inhaler Airmax™. Respir. Med., 96, 389-396.
40. Kohler, D. (2004). The Novolizer® : Overcoming inherent problems of dry powder inhalers. Respir. Med., 98, S17-S21.
41. Kunkel, G., Schaper, C., Noga, O., Schlafke, S., Lemmnitz, G., & Kohler, S. (2003). Efficacy, safety, and acceptance of beclomethasone dipropionate administered via a new dry powder inhaler or a standard CFC metered-dose inhaler in asthma patients. Respiration, 70, 399-406.
42. Labiris, N. R., & Dolovich, M. B. (2003a). Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 56, 588-599.
43. Labiris, N. R., & Dolovich, M. B. (2003b). Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 56, 600-612.
44. Leach, C. L., Davidson, P. J., & Boudreau, R. J. (1998). Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J., 12, 1346-1353.
45. Lehto, V. P., & Lankinen, T. (2004). Moisture transfer into medicament chambers equipped with a double-barrier-desiccant system. Int. J. Pharm., 275, 155-164.
46. Lewis, D. (2007). Metered-dose inhalers: Actuators old and new. Expert Opin. Drug Deliv., 4, 235-245.
47. Lim, J. G., Shah, B., Rohatagi, S., & Bell, A. (2006). Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships. Am. J. Ther., 13, 32-42.
48. Maggi, L., Bruni, R., & Conte, U. (1999). Influence of the moisture on the performance of a new dry powder inhaler. Int. J. Pharm., 177, 83-91.
49. Mandal, T. K. (2005). Inhaled insulin for diabetes mellitus. Am. J. Health Syst. Pharm., 62, 1359-1364.
50. Mayer, J. P., Zhang, F., & DiMarchi, R. D. (2007). Insulin structure and function. Biopolymers, 88, 687-713.
51. McDonald, K. J., & Martin, G. P. (2000). Transition to CFC-free metered dose inhalers-into the new millennium. Int. J. Pharm., 201, 89-107.
52. Meakin, B. J., Cainey, J., & Woodcock, P. M. (1993). Effect of exposure to humidity on turbutaline delivery from tubuhaler dry powder inhalation devices. Eur. Respir. J., 6, 760-761.
53. Melchor, R., Biddiscombe, M. F., Mak, V. H. F., Short, M. D., & Spiro, S. G. (1993). Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible air-flow obstruction. Thorax, 48, 506-511.
54. Molina, M. J., & Rowland, F. S. (1974). Stratospheric risk for chlorofluoromethanes: Chlorine atom-catalysed destruction of ozone. Nature, 249, 810-812.
55. Moore, A. C., & Stone, S. (2004). Meeting the needs of patients with COPD: Patients' preference for the Diskus inhaler compared with the Handihaler. Int. J. Clin. Pract., 58, 444-450.
56. Morton, D., & Staniforth, J. (2006). Systemic pulmonary delivery: Success through integrated formulation and device development. http://www.ondrugdelivery.com/publications/pulmonary.pdf.
57. Muchmore, D. B., Silverman, B., de la Pena, A., & Tobian, J. (2007). The AIR® Inhaled Insulin System: System components and pharmacokinetic/ glucodynamic data. Diabetes Technol. Ther., 9, S41-S47.
58. Musante, C. J., Schroeter, J. D., Rosati, J. A., Crowder, T. M., Hickey, A. J., & Martonen, T. B. (2002). Factors affecting the deposition of inhaled porous drug particles. J. Pharm. Sci., 91, 1590-1600.
59. Nelson, H., Kemp, J. P., Bieler, S., Vaughan, L. M., & Hill, M. R. (1999). Comparative efficacy and safety of albuterol sulfate spiros inhaler and albuterol metered-dose inhaler in asthma. Chest, 115, 329-335.
60. Newhouse, M. T., Hirst, P. H., Duddu, S. P., Walter, Y. H., Tarara, T. E., Clark, A. R., & Weers, J. G. (2003). Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest, 124, 360-366.
61. Newhouse, M. T., Nantel, N. P., Chambers, C. B., Pratt, B., & Parry-Billings, M. (1999). Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest, 115, 952-956.
62. Newman, S. P. (1990). Metered dose pressurized aerosols and the ozone layer. Eur. Respir. J., 3, 495-497.
63. Newman, S. P., Hollingworth, A., & Clark, A. R. (1994). Effect of different modes of inhalation on drug-delivery from a dry powder inhaler. Int. J. Pharm., 102, 127-132.
64. Newman, S., Malik, S., Hirst, P., Pitcairn, G., Heide, A., Pabst, J., Dinkelaker, A., & Fleischer, W. (2002). Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Respir. Med., 96, 1026-1032.
65. Newman, S. P., Pitcairn, G. R., Hirst, P. H., Bacon, R. E., O'Keefe, E., Reiners, M., & Hermann, R. (2000). Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur. Respir. J., 16, 178-183.
66. O'Connor, B. J. (2004). The ideal inhaler: Design and characteristics to improve outcomes. Respir. Med., 98, S10-S16.
67. Oenbrink, R. J. (1993). Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants. J. Am. Osteopath. Assoc., 93, 714-718.
68. Parry-Billings, M., Boyes, R. N., Clisby, L. M., Braithwaite, P., Williams, S., & Harper, A. E. (1999). Design, development and performance of a novel multidose dry-powder inhaler. Med. Device Technol., 10, 32-34.
69. Patton, J. S. (1996). Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev., 19, 3-36.
70. Patton, J. S. (1997). Deep-lung delivery of therapeutic proteins. Chemtech, 27, 34-38.
71. Patton, J. S. (2005). Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung. Diabetes, Obes. Metab., 7, S5-S8.
72. Patton, J. S., Bukar, J., & Nagarajan, S. (1999). Inhaled insulin. Adv. Drug Deliv. Rev., 35, 235-247.
73. Peart, J., & Clarke, M. J. (2001). New developments in dry powder inhaler technology. Am. Pharm. Rev., 4, 37-45.
74. Peart, J., Magyer, C., & Byron, P. R. (1998). Aerosol electrostatics - metered dose inhalers (MDIs): Reformulation and device design issues. Proceedings of Respiratory Drug Delivery VI, South Carolina, 227-233.
75. Pitcairn, G. R., Lankinen, T., Seppala, O. P., & Newman, S. P. (2000). Pulmonary drug delivery from the taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J. Aerosol Med., 13, 97-104.
76. Pitcairn, G. R., Lim, J., Hollingworth, A., & Newman, S. P. (1997). Scintigraphic assessment of drug delivery from the ultrahaler dry powder inhaler. J. Aerosol Med., 10, 295-306.
77. Pitcairn, G., Lunghetti, G., Ventura, P., & Newman, S. (1994). A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler. Int. J. Pharm., 102, 11-18.
78. Rave, K., Nosek, L., Heinemann, L., Gonzales, C., Ernest, C. S., Chien, J., & Muchmore, D. (2004). Inhaled micronized crystalline human insulin using a dry powder inhaler: Dose-response and time-action profiles. Diabet. Med., 21, 763-768.
79. Richardson, P. C., & Boss, A. H. (2007). Technosphere® Insulin technology. Diabetes Technol. Ther., 9, S65-S72.
80. Richter, K. (2004). Successful use of DPI systems in asthmatic patients-key parameters. Respir. Med., 98, S22-S27.
81. Saint-Lorant, G., Leterme, P., Gayot, A., & Flament, M. P. (2007). Influence of carrier on the performance of dry powder inhalers. Int. J. Pharm., 334, 85-91.
82. Sarinas, P. S. A., Robinson, T. E., Clark, A. R., Canfield, J., Chitkara, R. K., & Fick, R. B. (1998). Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest, 114, 988-992.
83. Sebti, T., Pilcer, G., Van Gansbeke, B., Goldman, S., Michils, A., Vanderbist, F., & Amighi, K. (2006). Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur. J. Pharm. Biopharm., 64, 26-32.
84. Shoyele, S. A., & Slowey, A. (2006). Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int. J. Pharm., 314, 1-8.
85. Smith, I. J., & Parry-Billings, M. (2003). The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther., 16, 79-95.
86. Smyth, H. D. C., & Hickey, A. J. (2005). Carriers in drug powder delivery: Implications for inhalation system design. Am. J. Drug Deliv., 3, 117-132.
87. Stanescu, D., Veriter, C., & Van de Woestijne, K. P. (2000). Maximal inspiratory flow rates in patients with COPD. Chest, 118, 976-980.
88. Steckel, H., & Muller, B. W. (1997). In vitro evaluation of dry powder inhalers. 1. Drug deposition of commonly used devices. Int. J. Pharm., 154, 19-29.
89. Steckel, H., Markefka, P., TeWierik, H., & Kammelar, R. (2004). Functionality testing of inhalation grade lactose. Eur. J. Pharm. Biopharm., 57, 495-505.
90. Tarsin, W. Y., Pearson, S. B., Assi, K. H., & Chrystyn, H. (2006). Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics. Int. J. Pharm., 316, 131-137.
91. Thibert, R., Parry-Billings, M., & Shott, M. (2002). Clickhaler® dry powder inhaler: Focussed in vitro proof of principle evaluation of a new chemical entity for asthma. Int. J. Pharm., 239, 149-156.
92. Tiddens, H. A., Geller, D. E., Challoner, P., Speirs, R. J., Kesser, K. C., Overbeek, S. E., Humble, D., Shrewsbury, S. B., & Standaert, T. A. (2006). Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol Med., 19, 456-465.
93. Tobyn, M., Staniforth, J. N., Morton, D., Harmer, Q., & Newton, M. E. (2004). Active and intelligent inhaler device development. Int. J. Pharm., 277, 31-37.
94. Valente, A., Langer, R., Stone, H. A., & Edwards, D. A. (2003). Recent advances in the development of an inhaled insulin product. BioDrugs, 17, 9-17.
95. Vanbever, R., Mintzes, J. D., Wang, J., Nice, J., Chen, D. H., Batycky, R., Langer, R., & Edwards, D. A. (1999). Formulation and physical characterization of large porous particles for inhalation. Pharm. Res., 16, 1735-1742.
96. Vaswani, S. K., & Creticos, P. S. (1998). Metered dose inhaler: Past, present, and future. Ann. Allergy Asthma Immunol., 80, 11-19.
97. Vidgren, M., Arppe, J., Vidgren, P., Hyvarinen, L., Vainio, P., Silvasti, M., & Tukiainen, H. (1994). Pulmonary deposition and clinical response of TC-99m-labeled salbutamol delivered from a novel multiple-dose powder inhaler. Pharm. Res., 11, 1320-1324.
98. Vidgren, M. K. A., Karkkainen, A., Karjalainen, P., Nuutinen, J., & Paronen, P. (1988). Effect of powder inhaler design on drug deposition in the respiratory tract. Int. J. Pharm., 42, 211-216.
99. Vidgren, M., Silvasti, M., Vidgren, P., Sormunen, H., Laurikainen, K., & Korhonen, P. (1995). Easyhaler® multiple-dose powder inhaler-practical and effective alternative to the pressurized MDI. Aerosol Sci. Technol., 22, 335-345.
100. Voss, A., & Finlay, W. H. (2002). Deagglomeration of dry powder pharmaceutical aerosols. Int. J. Pharm., 248, 39-50.
101. Warren, S., & Taylor, G. (1998). Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (DPI, clickhaler), a conventional metered dose inhaler(MDI), and MDI plus spacer. Respir. Drug Deliv., VI, 453-455.
102. Warren, S., Taylor, G., Godfrey, C., Cote, G., & Hill, M. (1999). Gamma scintigraphic evaluation of dry powder beclomethasone dipropionate (BDP) from an investigational spiros® inhaler: Effect of inspiratory flow profile on pulmonary drug deposition. Am. J. Respir. Crit. Care Med., 159, A118-A118.
103. Young, P. M., Price, R., Tobyn, M. J., Buttrum, M., & Dey, F. (2003). Investigation into the effect of humidity on drug-drug interactions using the atomic force microscope. J. Pharm. Sci., 92, 815-822.
104. Zeidler, M., & Corren, J. (2004). Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat. Respir. Med., 3, 35-44.
105. Zeng, X. M., Jones, S., O'Leary, D., Phelan, M., & Colledge, J. (2002a). Delivery of formoterol from a novel multi-dose inhaler Airmax™. Respir. Med., 96, 397-403.
106. Zeng, X. M., Martin, G., & Marriot, C. (2001). Particulate interactions in dry powder formulations for inhalation. Taylor and Francis, New York.
107. Zeng, X. M., O'Leary, D., Phelan, M., Jones, S., & Colledge, J. (2002b). Delivery of salbutamol and of budesonide from a novel multi-dose inhaler Airmax™. Respir. Med., 96, 404-411.